| abstract |
Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructive pulmonary disease, of the formula: <CHEM> wherein j is 0 or 1, k is 0 or 1, m is 0, 1, or 2; n is 1 or 2; A is is selected from the partial Formulas: <CHEM> where q is 1, 2, or 3, W<3> is -O-; -N(R<9>)-; or -OC(=O)-; R<7> is selected from -H; -(C1-C6)alkyl, -(C2-C6)alkenyl, or -(C2-C6)alkynyl substituted by 0 to 3 substituents R<10>; -(CH2)u-(C3-C7) cycloalkyl where u is 0, 1 or 2, substituted by 0 to 3 R<10>; and phenyl or benzyl substituted by 0 to 3 R<14>; R<8> is tetrazol-5-yl; 1,2,4-triazol-3-yl; 1,2,4-triazol-3-on-5-yl; 1,2,3-triazol-5-yl; imidazol-2-yl; imidazol-4-yl; imidazolidin-2-on-4-yl; 1,3,4-oxadiazolyl; 1,3,4-oxadiazol-2-on-5-yl; 1,2,4-oxadiazol-3-yl; 1,2,4-oxadiazol-5-on-3-yl; 1,2,4-oxadiazol-5-yl; 1,2,4-oxadiazol-3-on-5-yl; 1,2,5-thiadiazolyl; 1,3,4-thiadiazolyl; morpholinyl; parathiazinyl; oxazolyl; isoxazolyl; thiazolyl; isothiazolyl; pyrrolyl; pyrazolyl; succinimidyl; glutarimidyl; pyrrolidonyl; 2-piperidonyl; 2-pyridonyl; 4-pyridonyl; pyridazin-3-onyl; pyridyl; pyrimidinyl; pyrazinyl; pyridazinyl; indolyl; indolinyl; isoindolinyl; benzoÄbÜfuranyl; 2,3-dihydrobenzofuranyl; 1,3-dihydroisobenzofuranyl; 2H-1-benzopyranyl; 2-H-chromenyl; chromanyl; benzothienyl; 1H-indazolyl; benzimidazolyl; benzoxazolyl; benzisoxazolyl; benzothiazolyl; benzotriazolyl; benzotriazinyl; phthalazinyl; 1,8-naphthyridinyl; quinolinyl; isoquinolinyl; quinazolinyl; quinoxalinyl; pyrazoloÄ3,4-dÜpyrimidinyl; pyrimidoÄ4,5-dÜpyrimidinyl; imidazoÄ1,2-aÜpyridinyl; pyridopyridinyl; pteridinyl; or 1H-purinyl; or A is selected from phosphorous and sulfur acid groups; W is -O-; -S(=O)t-, where t is 0, 1, or 2; or -N(R<3>)-; Y is C(R<1>a)-, or -ÄN &squ& (O)kÜ where k is 0 or 1; R<4>, R<5> and R<6> are (1)-H; provided that R<5> and R<6> are not both -H at the same time, -F; -Cl; -(C2-C4) alkynyl; -R<16>; -OR<16>; -S(=O)pR<16>; -C(=O)R<16>, -C(=O)OR<16>; -OC(=O)R<16>; -CN; -NO2; -C(=O)NR<16>R<17>; -OC(=O)NR<16>R<17>; -NR<12>aC(=O)NR<16>R<17>; -NR<12>aC(=NR<12>)NR<16>R<17>; -NR<12>aC(=NCN)NR<15>R<16>; -NR<12>aC(=N-NO2)NR<15>R<16>; -C(=NR<12>a)NR<15>R<16>; -CH2C(=NR<12>a)NR<16>R<17>; -OC(=NR<12>a)NR<16>R<17>; -OC(=N-NO2)NR<16>R<17>; -NR<16>R<17>; -CH2NR<16>R<17>; -NR<12>aC(=O)R<16>; -NR<12>aC(=O)OR<16>; =NOR<16>; -NR<12>aS(=O)pR<17> -S(=O)pNR<16>R<17>; and -CH2C(=NR<12>a)NR<16>R<17>; (2) -(C1-C4) alkyl including dimethyl and -(C1-C4) alkoxy substituted with 0 to 3 substituents -F or -Cl; or 0 or 1 substituent (C1-C2) alkoxycarbonyl-, (C1-C2) alkylcarbonyl-, or (C1-C2) alkylcarbonyloxy-; or (3) an aryl or heterocyclic moiety; or (4) R<5> and R<6> are taken together to form a moiety of partial Formulas (1.3.1) through (1.3.15): <CHEM> B<1> and B<2> is a moiety comprising a saturated or unsaturated carbon ring system that is 3- to 7-membered monocyclic, or that is 7- to 12-membered, fused or discontinuous, polycyclic; wherein optionally one carbon atom thereof may be replaced by a heteroatom selected from N, O and S; and where N is selected, optionally a second carbon atom thereof may be replaced by a heteroatom selected from N, O, or S; or a pharmaceutically acceptable salt thereof.l |